Characterization of caspase‐2 inhibitors based on specific sites of caspase‐2‐mediated proteolysis

URN to cite this document:: urn:nbn:de:bvb:355-epub-528731
DOI to cite this document:: 10.5283/epub.52873

Bresinsky, Merlin ; Strasser, Jessica M. ; Hubmann, Alexander ; Vallaster, Bernadette ; McCue, William M. ; Fuller, Jessica ; Singh, Gurpreet ; Nelson, Kathryn M. ; Cuellar, Matthew E. ; Finzel, Barry C. ; Ashe, Karen H. ; Walters, Michael A. ; Pockes, Steffen

License: Creative Commons Attribution 4.0
PDF - Published Version
(2MB)

Date of publication of this fulltext: 20 Sep 2022 05:45

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Since the discovery of the caspase-2 (Casp2)-mediated ∆tau314 cleavage product and its associated impact on tauopathies such as Alzheimer's disease, the design of selective Casp2 inhibitors has become a focus in medicinal chemistry research. In the search for new lead structures with respect to Casp2 selectivity and drug-likeness, we have taken an approach by looking more closely at the specific ...